EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Larimar Therapeutics, Inc (LRMR) fair value: what the stock is really worth

As of Sep 25, 2026: fair value of Larimar Therapeutics, Inc $0.60, price $3.08, upside -80.4%, quality 27 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US5171251003

LT Larimar Therapeutics, Inc logo Thin data Sep 24, 2026

Larimar Therapeutics, Inc

LRMR · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $0.6035 · Strongly overvalued (−80%)
!Quality 27/100
!Low debt · negative free cash flow
!Trails peers (2/8)
!Narrow moat 6/100
!Evidence only low, so the estimate is less certain
Watch Larimar Therapeutics, Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$15.11 $1.53 Fair Value $0.6035 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $1.53 – $15.11 · fair‑value band $0.3995 – $0.7565 · the $3.08 price screens above the $0.6035 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow Larimar Therapeutics in your weekly email

Every Wednesday you see whether Larimar Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.

Show more

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.

Stock analysis

Larimar Therapeutics, Inc (LRMR) currently trades at $3.08, while our model-based Fair Value estimate is $0.6035, implying the stock looks roughly 409.4% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.

Scenario range: $0.3995 (bear) to $0.7565 (bull), the price of $3.08 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector.

Larimar Therapeutics, Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$166M in FY2025.

Key figures

Market cap $408M · EPS (TTM) $−2.03 · Return on equity −140% · Return on assets (EBIT) −60.0% · Free cash flow −$113M · Net cash $81.3M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).

What moves the price

The share trades about 48% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −4% fair-value upside, at −80%, LRMR screens richer than that median.

Fair Value models

Bear $0.3995 Fair Value $0.6035 Bull $0.7565
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.3800 $0.5000 $0.7500 54
All 1 models by family
Asset-Based
NCAV (Graham) $0.3800 $0.5000 $0.7500 54

Open the full fair value analysis →

Notify me when LRMR reaches fair value

Put LRMR on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 27/100

Of which business quality 30 · Market factors (momentum, volatility) 20

Profitability 0
Margins and returns on capital today
Quality Growth 25
Are margins and returns improving?
Cashflow 12
Earnings quality: real cash, not paper profit
Fin. Strength 69
Balance sheet, leverage, solvency risk
Investment 88
Disciplined investing over empire-building
Low Volatility 41
Calm price path (market factor)
Momentum 16
Price trend over the last 3–12 months (market factor)
52W Momentum 4
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

LRMR screens 409% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare Larimar Therapeutics, Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 658 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 30 · Bottom 25%
Fair Value upside −82% · Bottom 25%
Profitability
Return on assets −71% · Bottom 25%
Operating margin (TTM) 0% · Above median
Growth and dividend
Revenue growth 0% · Above median
Balance sheet
Debt / equity 0.11× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 5.23× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)95 · sector 97
DIVIDEND (yield)0 · sector 23

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $522.38 $574.62 +10%
Regeneron Pharmaceuticals, Inc REGN $788.04 $1,275 +62%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$176.95 A$194.65 +10%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Larimar Therapeutics, Inc · Fair Value
$0.6035 −409%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Larimar Therapeutics, Inc Fair Value". https://www.fairvalue-calculator.com/stock/LRMR

Frequently asked questions

Is Larimar Therapeutics, Inc (LRMR) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.6035 versus a price of $3.08, about −80% upside (overvalued).
What is the fair value of LRMR?
Our model-based fair value for Larimar Therapeutics, Inc is $0.6035 (as of Sep 24, 2026), built from audited fundamentals. The current price: $3.08.
What is the quality score of LRMR?
Larimar Therapeutics, Inc has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Larimar Therapeutics, Inc (LRMR)?
Our model-based price target is the fair value of $0.6035 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $0.3995, optimistic scenario $0.7565. It is a calculation from audited fundamentals, not an analyst target.
What is the Larimar Therapeutics, Inc stock forecast for 2026?
Our models put fair value at $0.6035, about −80% upside versus a price of $3.08 (overvalued). Cautious scenario $0.3995, optimistic scenario $0.7565. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Larimar Therapeutics, Inc (LRMR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Larimar Therapeutics, Inc it is $0.6035 per share (as of Sep 24, 2026), against a price of $3.08. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Larimar Therapeutics, Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, LRMR trades above its calculated fair value: price $3.08, fair value $0.6035, a gap of about −80% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LRMR?
No. The price is what the market pays today ($3.08); the fair value is what the company's own numbers justify ($0.6035). For Larimar Therapeutics, Inc the two are $2.47 per share apart. That gap is exactly why we show both numbers side by side.
How much is Larimar Therapeutics, Inc worth?
The market values Larimar Therapeutics, Inc at about $408M (market capitalisation, as of Sep 24, 2026). Per share that is $3.08; our models calculate a fair value of $0.6035 per share.
What do the bullish and bearish scenarios say about LRMR?
Our models span a range for Larimar Therapeutics, Inc: cautious scenario $0.3995, base $0.6035, optimistic $0.7565 per share (as of Sep 24, 2026, price $3.08). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Larimar Therapeutics, Inc (LRMR)?
Balance-sheet figures for Larimar Therapeutics, Inc (as of Sep 24, 2026): return on equity −139.6%, debt of 0.11 per unit of equity. They feed the Quality Score of 27/100, which measures business quality independently of the share price.
How far is LRMR from its 52-week high?
Larimar Therapeutics, Inc trades at $3.08, about 48% below its 52-week high of $5.95 and 9% above the low of $2.81 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.6035 is for.
Which stocks are comparable to Larimar Therapeutics, Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Larimar Therapeutics, Inc stock attractive at the current price?
The data as of Sep 24, 2026: price $3.08, calculated fair value $0.6035 (−80%), Quality Score 27/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LRMR calculated?
We run Larimar Therapeutics, Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.6035, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Larimar Therapeutics, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Larimar Therapeutics, Inc (LRMR)?
The closing price on Sep 25, 2026 was $3.08. Our model-based fair value is $0.6035, about −80% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Larimar Therapeutics, Inc right now?
The price sits above even our optimistic bull case ($0.7565). The favourable scenario is already priced in. Weak quality (27/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.3995 to $0.7565) leaves room in how you read the outcome.

Key figures of Larimar Therapeutics, Inc

How large is the market capitalisation of Larimar Therapeutics, Inc (LRMR)?
The market capitalisation of Larimar Therapeutics, Inc is $408M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Larimar Therapeutics, Inc (LRMR)?
Earnings per share at Larimar Therapeutics, Inc are $−2.03. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Larimar Therapeutics, Inc (LRMR)?
The return on equity (ROE) of Larimar Therapeutics, Inc is −140% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Larimar Therapeutics, Inc (LRMR)?
On an EBIT basis the return on assets of Larimar Therapeutics, Inc is −60.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Larimar Therapeutics, Inc (LRMR) generate?
The free cash flow of Larimar Therapeutics, Inc is −$113M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Larimar Therapeutics, Inc (LRMR) hold?
Larimar Therapeutics, Inc holds more cash than debt, $81.3M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Larimar Therapeutics, Inc in the live analysis

One click puts Larimar Therapeutics, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.